A study to compare continuous infusion and intermittent injections of furosemide and amiloride hydrochloride in patients hospitalized with acute heart failure and fluid overload

1 1 1 1

What is this study about?

This study focuses on Acute Heart Failure with volume overload, a condition where the heart cannot pump blood effectively, leading to an excess of fluid buildup in the body. The purpose of the study is to compare two different ways of giving the medication furosemide to see which method works better at removing extra fluid. Furosemide is a type of diuretic, which is a medication used to help the body get rid of extra salt and water through urination.

Participants in the study will receive the medication through an intravenous method, meaning it is delivered directly into a vein. One group will receive the drug through a bolus injection, which is a single, rapid dose given at specific times of the day. The other group will receive a continuous infusion, where the medication is delivered steadily over a period of time. This study aims to determine if the way the medicine is administered affects how well the body eliminates the excess fluid.

Who Can Join the Study?

  • You must have a diagnosis of acute heart failure with volume overload, which means your heart is temporarily unable to pump enough blood, causing extra fluid to build up in your body.
  • You must show at least one sign of volume overload, such as swelling in your legs or fluid in your lungs.
  • You are expected to receive intravenous furosemide for at least 3 days. This is a type of medicine called a diuretic (a drug that helps your body get rid of extra water and salt through urine) that is given directly into a vein through a needle or tube.
  • You must be 18 years of age or older.

Who Cannot Join the Study?

  • You are experiencing shock, which is a life-threatening condition where the body does not get enough blood flow.
  • You need medications called inotropes or vasopressors, which are drugs used to help the heart pump stronger or to tighten blood vessels to increase blood pressure.
  • You are currently using or planning to use renal replacement therapy or ultrafiltration, which are medical treatments used to do the work of the kidneys, such as dialysis.
  • You have had a renal transplant, meaning you have received a transplanted kidney.
  • You are currently pregnant or breastfeeding.
  • You have severe hypokalaemia, which is a very low level of potassium (a mineral needed for muscles and nerves) in your blood.
  • You have severe hyponatremia, which is a very low level of sodium (a mineral that helps balance fluids) in your blood.
  • You have an allergy to furosemide or any of the ingredients used to make it.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
Region Midtjylland Aarhus Denmark
Sygehus Soenderjylland Soenderborg Aabenraa Denmark
Rrlyiq Nsycrthysxe Aalborg Denmark

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Denmark Denmark
Not yet recruiting
01.05.2026

Trial locations

Furosemide is a medication used to help the body get rid of excess water and salt through urine. In this study, it is being tested to see if it works better when given as a steady drip into a vein or when given as separate quick injections several times a day to help patients with sudden heart failure.

Acute heart failure with volume overload – This condition occurs when the heart cannot pump blood effectively enough to meet the body’s needs. As a result, excess fluid begins to build up in the body’s tissues and organs. This buildup often leads to swelling in the legs and accumulation of fluid in the lungs. The progression involves increasing pressure within the blood vessels. This pressure can make breathing more difficult as fluid enters the airways. The condition is characterized by this rapid accumulation of excess water and salt in the system.

Trial ID:
2025-523589-26-00
Protocol code:
INFUSE-AHF
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Study of empagliflozin compared to placebo in patients with acute decompensated heart failure who are already taking SGLT2 inhibitors

    Recruiting

    1 1 1
    Investigated drugs:
    Germany
  • Study on Early Use of Ivabradine for Children with Heart Failure Due to Dilated Cardiomyopathy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy